Clinical Trials Logo

Leishmaniasis, Visceral clinical trials

View clinical trials related to Leishmaniasis, Visceral.

Filter by:

NCT ID: NCT00255567 Completed - Clinical trials for Visceral Leishmaniasis

Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of SSG 30 days alone, PM 21 days alone and SSG and PM as a combination course of 17 days in the treatment of patients with VL.

NCT ID: NCT00216346 Completed - Clinical trials for Visceral Leishmaniasis

Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis

Start date: June 2003
Phase: Phase 3
Study type: Interventional

Symptomatic Visceral Leishmaniasis(VL)is fatal; Due to the increasing resistance to standard therapy with antimonials, there is a need for new safe, efficacious, low-cost therapies for the treatment of VL. Paromomycin is an off-patent aminoglycoside antibiotic with anti-leishmaniasis activity. This study will test the safety and efficacy of paromomycin in the treatment of patients with VL in India.

NCT ID: NCT00001169 Completed - Leishmaniasis Clinical Trials

Clinical Investigation of Infections Due to Leishmanial Parasites

Start date: December 1979
Phase: N/A
Study type: Observational

Mechanisms of host immune response to intracellular protozoa will be investigated in patients with naturally acquired infection employing a variety of in-vitro techniques. Both non-specific and antigen-specific humoral and cellular immune responses will be assessed. Parasites will be isolated from patients, cultivated in-vitro, and characterized. Responses to chemotherapy will be assessed parasitologically, immunologically and clinically.